The FDA has approved lumateperone for the prevention of relapse in schizophrenia, expanding its therapeutic indication for this atypical antipsychotic.
The FDA has paused Newron's Phase 3 schizophrenia trial following a patient death, signaling a critical safety signal that may impact the development of this investigational antipsychotic.
A patient death has halted Newron's late-stage clinical trial for a schizophrenia treatment, representing a significant setback in the drug development pipeline for this indication.
The FDA has imposed a clinical hold on Newron's schizophrenia trial following a patient death, signaling a significant safety concern that may delay or halt development of this investigational psychotropic.
A medication shortage for ADHD treatments in Japan is disrupting patient care, highlighting supply chain vulnerabilities in psychopharmacology.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Feb 25 – Apr 30)
- Utilize the updated FDA labeling for lumateperone (Caplyta) to offer a maintenance therapy option for schizophrenia relapse prevention in patients who have stabilized on acute treatment.
- Consider ecopipam as a later-line therapeutic option for Tourette syndrome, particularly when standard antipsychotics or alpha-2 agonists are ineffective or poorly tolerated due to its distinct D1 antagonist mechanism.
- Apply the CYPRI tool to prioritize patients for CYP2D6/CYP2C19 pharmacogenetic testing, thereby improving the cost-effectiveness of personalized psychopharmacology by focusing on those most likely to yield actionable results.
- Monitor for age-specific suicide risk signals when prescribing montelukast or sertraline to youth and hydrocodone/acetaminophen to elderly patients, based on recent FAERS safety data.
- Incorporate the Tardive Dyskinesia Impact Scale (TDIS) into clinical assessments to capture the socioemotional benefits of VMAT2 inhibitors like valbenazine, providing a more comprehensive evaluation of treatment efficacy beyond motor symptoms.
- Advocate for reduced antipsychotic polypharmacy and increased clozapine utilization in schizophrenia management, supported by meta-analytic data showing high rates of polypharmacy in MENAT/EMRO regions.
- Use patient-selected music as an adjunctive intervention during intranasal esketamine treatment to mitigate transient dissociative and ataxic side effects, potentially improving tolerability and adherence.
- Consider long-acting injectable paliperidone for pediatric patients with traumatic brain injury and post-traumatic aggression who have poor oral adherence and have failed standard oral therapies.
- Emphasize early detection and intervention in first-episode schizophrenia, as shorter duration of untreated psychosis is a strong predictor of better short-term symptom improvement.
Policy & Regulation 2
The FDA has placed a clinical hold on Newron's Phase 3 schizophrenia trial following a patient death, signaling a significant regulatory setback for the investigational psychotropic drug.
The MHRA has issued a recall for a popular antidepressant after patients discovered the bottle contained the wrong medication, highlighting a critical patient safety and prescribing error.
Drug Development 3
This systematic review protocol aims to synthesize human neuroimaging data on dopaminergic dysregulation in opioid use disorder to identify mechanistic targets for novel pharmacotherapies beyond current mu-opioid receptor agonists.
Teva acquired Emalex for $700M to advance its experimental drug for Tourette syndrome, signaling continued investment in neurologic and psychiatric therapeutic pipelines.
This article discusses the investigation of psilocybin's effects in treatment-resistant depression, representing research into a psychedelic compound with psychiatric therapeutic potential.
Clinical Pearl 5
This case report suggests low-dose mirtazapine as a viable pharmacologic alternative to SSRIs for treating compulsive polydipsia in autistic patients, avoiding the risk of SSRI-induced hyponatremia.
This case report describes the use of patient-selected music as an adjunctive intervention to mitigate transient dissociative and ataxic side effects during intranasal esketamine treatment for treatment-resistant depression, potentially improving tolerability and adherence.
A clinical trial is recruiting to evaluate the efficacy and safety of the dual orexin receptor antagonist daridorexant for treating insomnia in patients with major depressive disorder.
A case report demonstrates that long-acting injectable paliperidone effectively reduced post-traumatic aggression in a pediatric TBI patient with poor oral adherence, highlighting its potential utility for behavioral dysregulation when standard oral therapies fail.
Clinical trial data support the safety and efficacy of extended-release buprenorphine for treating opioid use disorder in pregnant individuals.
Diagnosis & Treatment 5
A new predictive tool (Obscore) integrates BMI, family history, and socioeconomic factors to identify patients at risk for 18 obesity-related complications, aiding in the selection of candidates for GLP-1 obesity pharmacotherapy.
A pilot trial demonstrates that combining cognitive behavioral therapy with psilocybin produces rapid, significant, and sustained relief of major depression symptoms.
Patients in forensic psychiatry wards generally accept their illness and hold positive attitudes toward pharmacotherapy, suggesting that individualized treatment approaches are warranted rather than assuming resistance to medication.
A study reveals that over 50% of older dementia patients continue psychotropic medications one year after initiation, highlighting persistent prescribing patterns relevant to deprescribing efforts.
A large South Korean study published in The BMJ finds no increased risk of psychiatric or neurodevelopmental disorders in children whose mothers used sedatives (benzodiazepines or Z-hypnotics) during pregnancy.
Mechanism of Action 2
This study analyzes intracranial neural activity in three treatment-resistant depression patients to characterize the network effects of combinatorial deep brain stimulation targets, providing mechanistic insights for optimizing surgical parameters.
This study characterizes the acute dose-dependent effects of the psychedelic 2C-B relative to MDMA and psilocybin in healthy volunteers, providing mechanistic insights into psychedelic pharmacology relevant to future psychiatric therapeutic development.
Substance Use 1
Qualitative study reveals that people who use drugs are willing to use higher dose naloxone for opioid overdoses but remain skeptical due to concerns about precipitated withdrawal and pharmaceutical marketing.
Pharmacogenomics 1
The CYPRI tool helps psychiatrists prioritize patients for CYP2D6/CYP2C19 pharmacogenetic testing by estimating the likelihood of actionable results, potentially improving cost-effectiveness in psychopharmacology.
Journal Article 1
A meta-analysis reveals that antipsychotic polypharmacy affects 50% of schizophrenia patients in MENAT/EMRO regions, prompting recommendations to reduce polypharmacy and increase clozapine utilization.
Digital Health 2
The PETRUSHKA tool, developed by Andrea Cipriani, improves antidepressant persistence in patients with major depressive disorder, offering a practical strategy to enhance medication adherence.
This systematic review evaluates intracranial neural biomarkers to guide closed-loop neuromodulation therapies for treatment-resistant psychiatric disorders, highlighting the need to account for disorder-specific symptom time constants.